Overview

PK,PD, Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Lenalidomide for the Treatment of Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (MT-3724_NHL_003)

Status:
Terminated

Trial end date:
2021-03-10

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the safety and tolerability of MT-3724 in combination with Lenalidomide in subjects with relapsed or refractory B-Cell NHL.

Phase:

Phase 2

Details

Lead Sponsor:

Molecular Templates, Inc.

Treatments:

Lenalidomide